IP Library Granted Patent US 8,981,077
Granted Patent B2
US 8,981,077 · App. 13/968,497 · Granted Mar 17, 2015

Methods and compositions for extraction and storage of nucleic acids

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,981,077
App. No.
13/968,497
Granted
Mar 17, 2015
Kind
B2
Abstract

A solid matrix for the extraction, stabilization, and storage of nucleic acids is provided. At least one protein denaturant, and at least one acid or acid-titrated buffer reagent are impregnated in a dry state therein the matrix; and the matrix is configured to provide an acidic pH on hydration. The matrix is configured to extract nucleic acids from a sample and stabilize the extracted nucleic acids, particularly RNA, in a dry format under ambient conditions for a prolonged period of time. Methods for collecting and recovering the nucleic acids stored in the dry solid matrix are also described.

Claims (53)

1. A solid matrix, comprising:

at least one protein denaturant; and

at least one acid or acid-titrated buffer reagent impregnated therein in a dry state;

wherein the matrix is a non-dissolvable dry solid material and wherein the matrix is configured to provide an acidic pH upon hydration, extract nucleic acids from a sample, and preserve the nucleic acids in a substantially dry state at ambient temperature; and the acid-titrated buffer reagent generates a pH in a range from 3 to 6, wherein the matrix comprises cellulose, cellulose acetate, glass fiber or combinations thereof.

2. The matrix of claim 1 is a solid phase extraction matrix.

3. The matrix of claim 1 , wherein the extracted and preserved nucleic acids comprise ribonucleic acids (RNA), deoxy ribonucleic acids (DNA) or a combination thereof.

4. The matrix of claim 1 , wherein the extracted and preserved nucleic acids comprise RNA.

5. The matrix of claim 4 , wherein the extracted and preserved RNA has an RNA integrity number (RIN) of at least 4.

6. The matrix of claim 1 , wherein the acid comprises acetic acid, citric acid, tartaric acid, phosphoric acid, hydrochloric acid, Tris(2-carboxyethyl) phosphine-hydrochloric acid (TCEP-HCl), oxidized Tris(2-carboxyethyl) phosphine- hydrochloric acid (TCEP-O-HCl), sulfuric acid, nitric acid, vanillic acid, 3-(N-morpholino)propanesulfonic acid or combinations thereof.

7. The matrix of claim 1 further comprising a UV protectant, a free-radical scavenger, a chelator or combinations thereof.

8. The matrix of claim 7 , wherein the UV protectant or free-radical scavenger is selected from the group consisting of hydroquinone monomethyl ether (MEHQ), hydroquinone (HQ), toluhydroquinone (THQ), and ascorbic acid.

9. The matrix of claim 1 further comprising an RNase inhibitor.

10. The matrix of claim 9 , wherein the RNase inhibitor comprises a triphosphate salt, pyrophosphate salt or combinations thereof.

11. The matrix of claim 9 , wherein the RNase inhibitor comprises vanadyl ribonucleoside complex (VRC), sodium pyrophosphate, or a commercially available RNase inhibitor.

12. The matrix of claim 9 , wherein the RNase inhibitor comprises sodium triphosphate.

13. The matrix of claim 1 further comprising at least one reducing agent.

14. The matrix of claim 13 , wherein the reducing agent is selected from the group consisting of dithiothreitol (DTT), 2-mercaptoethanol (2-ME), tris(2-carboxyethyl)phosphine (TCEP), tris(2-carboxyethyl)phosphine hydrochloride (TCEP-HCl)and a combination thereof.

15. The matrix of claim 1 , wherein the matrix comprises cellulose, cellulose acetate, nitrocellulose, glass fiber or any combination thereof.

16. The matrix of claim 1 , wherein the matrix is porous.

17. The matrix of claim 1 , wherein the protein denaturant is selected from a group consisting of guanidinium hydrochloride, guanidinium thiocyanate, sodium thiocyanate, potassium thiocyanate, arginine, sodium dodecyl sulfate (SDS), urea and combinations thereof.

18. The matrix of claim 1 , wherein the sample is a biological sample.

19. An RNA extraction matrix comprising:

a protein denaturant comprising a chaotropic agent, a detergent or combinations thereof; and

an acid or acid-titrated buffer reagent impregnated therein in a dry state,

wherein the matrix is a porous non-dissolvable dry material configured to provide a pH in a range from 3 to 6 upon hydration for extracting RNA and stabilizing the extracted RNA with a RIN of at least 4, wherein the matrix comprises cellulose, cellulose acetate, glass fiber or combinations thereof.

20. The matrix of claim 19 further comprising a UV protectant or free-radical scavenger selected from the group consisting of MEHQ, HQ, THQ, ascorbic acid and combinations thereof.

21. An RNA extraction matrix comprising:

a protein denaturant comprising a chaotropic agent, a detergent or combinations thereof;

an acid or acid-titrated buffer reagent; and

an RNase inhibitor comprising a triphosphate salt or pyrophosphate salt impregnated therein in a dry state, wherein the matrix comprises a porous non-dissolvable dry material configured to provide a pH between 3 to 6 upon hydration and stabilize RNA with a RIN value of at least 4, wherein the matrix comprises cellulose, cellulose acetate, glass fiber or combinations thereof.

22. A method for extracting and storing nucleic acids from a sample, comprising:

providing the sample on a dry non-dissolvable solid matrix comprising;

a protein denaturant; and

an acid or acid-titrated buffer reagent;

generating an acidic pH upon hydration for extraction of nucleic acids from the sample, where the acidic pH is in a range from 3 to 6;

drying the matrix comprising the extracted nucleic acids; and

storing the extracted nucleic acids on the matrix in a substantially dry state at ambient temperature, wherein the matrix comprises cellulose, cellulose acetate, glass fiber or combinations thereof.

23. The method of claim 22 further comprising recovering the nucleic acids from the matrix.

24. The method of claim 23 , wherein the recovery of the nucleic acids from the matrix comprises rehydrating the matrix in an aqueous solution, a buffer or an organic solution.

25. The method of claim 23 , wherein the recovery of the nucleic acids from the matrix comprises electroelution.

26. The method of claim 22 , wherein the sample is a biological sample.

27. The method of claim 26 , wherein the biological sample comprises blood, serum, tissue, saliva, or cells.

28. The method of claim 26 , wherein the sample is a cell extract, a tissue culture cell preparation, an impure nucleic acidor a purified nucleic acid.

29. The method of claim 22 , wherein the extracted nucleic acids comprise RNA, DNA or a combination thereof.

30. The method of claim 22 , wherein the extracted nucleic acids comprise RNA.

31. The method of claim 30 , wherein the extracted RNA has a RIN of at least 4.

32. The method of claim 22 , wherein the matrix further comprises a UV protectant, a free-radical scavenger, a chelator or combinations thereof.

33. The method of claim 32 , wherein the UV protectant or free-radical scavenger is selected from the group consisting of MEHQ, HQ, THQ, and ascorbic acid.

34. The method of claim 22 , wherein the matrix further comprises an RNase inhibitor.

35. The method of claim 22 , wherein the matrix comprises a porous cellulose paper.

36. The method of claim 22 , wherein the protein denaturant is selected from the group consisting of guanidinium hydrochloride, guanidinium thiocyanate, sodium thiocyanate, potassium thiocyanate, arginine, SDS, urea and combinations thereof.

37. The method of claim 22 , wherein the matrix further comprises a reducing agent is selected from the group consisting of DTT, 2-ME, TCEP, TCEP-HCl and a combination thereof.

38. The method of claim 22 , wherein the acid comprises acetic acid, citric acid, tartaric acid, phosphoric acid, hydrochloric acid, TCEP-HCl , TCEP-O-HCl , sulfuric acid, nitric acid, vanillic acid, 3-(N-morpholino)propanesulfonic acid or combinations thereof

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 7, 2020
From: GE HEALTHCARE UK LIMITED
To: GLOBAL LIFE SCIENCES SOLUTIONS OPERATIONS UK LTD
Reel/Frame 054300/0369 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 5, 2020
From: GENERAL ELECTRIC COMPANY
To: GE HEALTHCARE UK LIMITED
Reel/Frame 053981/0329 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 16, 2013
From: KVAM, ERIK LEEMING; LI, BING; BALES, BRIAN CHRISTOPHER
To: GENERAL ELECTRIC COMPANY
Reel/Frame 031023/0786 →